These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15308510)

  • 21. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
    Varga J
    Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045
    [No Abstract]   [Full Text] [Related]  

  • 22. [Endothelin receptor antagonists in pulmonary arterial hypertension].
    Tokgöz HC; Can MM; Kaymaz C
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and endothelin receptor antagonist in primary Sjögren's syndrome with pulmonary arterial hypertension.
    Chen CH; Chen HA; Yang KY; Yu WC; Liao HT; Huang DF
    Scand J Rheumatol; 2006; 35(3):245-7. PubMed ID: 16766376
    [No Abstract]   [Full Text] [Related]  

  • 25. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Endothelin receptor antagonism in routine clinical care].
    Riemekasten G
    Krankenpfl J; 2005; 43(7-10):245. PubMed ID: 16515314
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
    Musch A
    Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelin receptor antagonists in preclinical models of pulmonary hypertension.
    Pullamsetti SS; Schermuly RT
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():3-13. PubMed ID: 19335741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A; Sakai E; Oyama N; Yamamoto T
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
    Neuhofer W; Gülberg V; Gerbes AL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():54-61. PubMed ID: 16919012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease.
    Krum H; Liew D
    Curr Opin Investig Drugs; 2003 Mar; 4(3):298-302. PubMed ID: 12744222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
    Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
    Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
    Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
    J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M; Kodric M; Longo C; Vassallo FG
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
    Ahmadi-Simab K; Lamprecht P; Hellmisch B; Gross WL
    Z Rheumatol; 2004 Dec; 63(6):495-7. PubMed ID: 15605216
    [No Abstract]   [Full Text] [Related]  

  • 38. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies.
    Davie NJ; Schermuly RT; Weissmann N; Grimminger F; Ghofrani HA
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():38-49. PubMed ID: 19335746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin receptor antagonists.
    Motte S; McEntee K; Naeije R
    Pharmacol Ther; 2006 Jun; 110(3):386-414. PubMed ID: 16219361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of pulmonary arterial hypertension.
    Judge EP; Gaine SP
    Curr Opin Crit Care; 2013 Feb; 19(1):44-50. PubMed ID: 23242212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.